Joseph H. Antin Received ASTCT Lifetime Achievement Award at 2025 Tandem Meetings
Dana-Farber Cancer Institute announced that Joseph H. Antin, MD, had been honored with the ASTCT Lifetime Achievement Award at the 2025 Tandem Meetings, the premier conference in hematopoietic cell transplantation (HCT) and cellular therapy. Organized by the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood and Marrow Transplant Research (CIBMTR), the event took place from February 12–15 in Honolulu, Hawaii.
This prestigious award recognizes exceptional contributions to the fields of bone marrow transplantation (BMT) and cellular therapy, honoring individuals who have significantly advanced knowledge through basic or clinical research.
About Dr. Joseph H. Antin
Dr. Antin is a Professor of Medicine at Harvard Medical School and holds the Jock and Bunny Adams Chair in Hematology. He earned his medical degree from Weill Medical College of Cornell University (1978), completed his residency at Peter Bent Brigham Hospital/Harvard Medical School (1981), and pursued fellowships at Brigham and Women’s Hospital (1982) and Dana-Farber Cancer Institute (1983).
From 1986 to 1997, he served as Chief of Stem Cell Transplantation at Brigham and Women’s Hospital. He later led the Stem Cell Transplant Program at Dana-Farber/Brigham and Women’s Cancer Center from 1997 to 2018 and now holds the title of Chief Emeritus.
Dr. Antin’s research focuses on graft-versus-host disease (GVHD) prevention and treatment and harnessing graft-versus-leukemia effects to combat blood disorders. His work includes clinical trials evaluating T-cell depletion, novel immunosuppressive agents, graft engineering, and vaccine development to improve transplantation outcomes.
Among his notable contributions, Dr. Antin:
- Co-developed the first use of molecular techniques to establish chimerism after transplantation (1984).
- Pioneered the application of PCR to detect and quantify residual BCR/ABL in stem cell transplantation (1989).
- Contributed to a landmark 1994 publication on donor lymphocyte infusions for relapsed CML.
- Co-introduced the concept of cytokine storm as a key mechanism in GVHD pathophysiology.
- Led groundbreaking research on GVHD prevention and therapy, including early tacrolimus development and the use of sirolimus in transplantation.
Beyond his research, Dr. Antin has mentored and trained numerous faculty members at Dana-Farber Cancer Institute, many of whom have become national and regional leaders in stem cell transplantation. His lifelong dedication to advancing transplantation science has left an indelible mark on the field.
Photo taken from Dana-Farber/X
Stay tuned to OncoDaily for further updates.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023